Autopsy report · NCT00509496
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Cause of deathSlow enrollment
“Low accrual”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 5 years 1 month before it stopped.
- 21 participants enrolled.
- Results were posted on the registry 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Skin Cancer; Melanoma
- Interventions
- fludarabine phosphate; cyclophosphamide; aldesleukin; autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes; autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
- Participants
- 21
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.